



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 3/10/03

Signature: Anna P. Lucey

(Anna P. Lucey)

Docket No.: ASZD-P01885  
(PATENT)

TECH CENTER  
MAR 17 2003  
1614

RECEIVED

#11  
A.G.J  
7/30/03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Luke et al.

Application No.: 09/786702

Group Art Unit: 1614

Filed: March 7, 2001

Examiner: Not Yet Assigned

For: PIPERIZINE-4-PHENYL DERIVATIVES AS  
INHIBITORS OF THE INTERACTION  
BETWEEN MDM2 AND P 53

### INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents  
Washington, DC 20231

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO/SB/08 is attached.

A summary/abstract translation of the non-English language references is enclosed.


While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents should one or more of the documents be applied against the claims of the present application.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-385.

Dated:

Respectfully submitted,

By   
David P. Halstead, Ph.D.

Registration No.: 44,735  
ROPES & GRAY  
One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicant

## INFORMATION DISCLOSURE CITATION

## IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)  
ASZD-P01-385Application Number  
09/786,702Applicant  
Luke et al.Filing Date  
March 7, 2001Group Art U  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AA DE 4243858 ✓	6/30/94	Germany			Abstract
	AB JP 05294915 ✓	11/9/93	Japan			Abstract
	AC WO 94/07496 ✓	4/14/94	WIPO			
	AD WO 95/34311 ✓	12/21/95	WIPO			
	AE WO 97/09343 ✓	3/13/97	WIPO			Abstract
	AF WO 97/37983	10/16/97	WIPO			Abstract
	AG WO 98/25617	6/18/98	WIPO			

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

AH	Barakat, K.J. et al. Synthesis and Biological Activities of Phenyl Piperazine-Based Peptidomimetic Growth Hormone Secretagogues. Bioorg. Med. Chem. Lett. 8, 1431-1436 (1998).
AI	Sakamoto, H. et al. Chymotrypsin Inhibition by Dipeptide Esters, Phenylpiperidide and Phenylpiperazides Pept. Chem. 27, 375-378 (1990).
AJ	Sakamoto, H. et al. Dipeptide Side Chain-Side Chain Hydrophobic Interactions as Conformational Core for Chymotrypsin Inhibition. Bull. Chem. Soc. Jpn 64, 2519-2523 (1991).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE